פרסומת

שיטה פוטנציאלית לטיפול באוסטאוארתריטיס על ידי מערכת מהונדסת ננו לאספקת תרופות חלבון

חוקרים יצרו ננו-חלקיקים מינרלים דו-מימדיים כדי לספק טיפול בגוף להתחדשות הסחוס

אוסטאוארתריטיס is a degenerative disease which affects 630 million people worldwide which is almost 15 percent of the entire population on the כוכב לכת. In osteoarthritis, cartilage in our bone starts breaking down and this can damage the underlying bone causing pain and stiffness, especially in knee, hip and thumb joints. The incidence of this condition increases as we age. Treatments for osteoarthritis include medications, physiotherapy, occupational therapy targeted mainly to relieve pain symptoms. To treat this condition entirely, damaged joint tissues need to be repaired. This repair is complicated and challenging as cartilage tissue in the bone is difficult to regenerate. As the world’s population is ageing, new effective treatments for osteoarthritis are immediately needed.

גורמי גדילה חלבון

A possible treatment of osteoarthritis involves design and delivery of חלבון therapeutics i.e. חלבונים engineered in laboratory for therapeutic use. חֶלְבּוֹן therapeutics have had a major impact on many diseases in recent decades. One such class of חלבונים is called growth factors which are soluble secreted חלבונים. Our body is capable of self-healing and this process can be enhanced by artificial application of growth factors to improve processes involved in self-healing. However, most of the known growth factors break down rapidly and thus very high dosage is needed to achieve a therapeutic effect. Studies have shown adverse effects of high dosage like inflammation and uncontrolled tissue formation. The application of growth factors is also very limited mainly due to lack of efficient delivery systems or biomaterial carriers. Growth factors along with efficient biomaterial delivery systems are critical in regenerative medicine involving tissue repair and regeneration.

טיפול חדש לאוסטאוארתריטיס המבוסס על ננוסיליקטים

Researchers at Texas A&M University, USA aimed to develop a novel treatment for cartilage regeneration by designing two-dimensional (2D) mineral nanoparticles which could be used to deliver growth factors. These nanoparticles (or nanosilicates) possess two key characteristics – high surface area and dual charge – which allow easier attachment of growth factors. Nanosilicates show higher binding efficacy to growth factors without affecting the protein’s 3D conformation or its biological function. They allow longer sustained delivery (more than 30 days) of growth factors to human mesenchymal stem cells which are then used in regeneration of cartilage by inducing enhanced differentiation of stem cells towards cartilage. Enhanced differentiation confirms high activity of the released חלבון and that also at 10-fold lower concentration compared to current therapies which use much higher dose.

מחקר זה פורסם ב חומרים וממשקים יישומיים של ACS shows a nanoengineered system – a nanoclay-based platform in which nanosilicates can be used as a delivery vehicle to enable sustained delivery of חלבון therapeutics for treating osteoarthritis. Such a biomaterial-based delivery system could ensure efficient treatment of osteoarthritis by reducing overall costs and minimizing negative side effects. This novel platform of delivery can boost current orthopaedic regeneration strategies and make an impact on regenerative medicine.

***

{תוכל לקרוא את עבודת המחקר המקורית על ידי לחיצה על קישור ה-DOI המופיע להלן ברשימת המקורות המצוטטים}

מקור (ים)

Cross LM et al 2019. Sustained and Prolonged Delivery of חֶלְבּוֹן Therapeutics from Two-Dimensional Nanosilicates. ACS Applied Materials & ממשקים. 11. https://doi.org/10.1021/acsami.8b17733

צוות SCIEU
צוות SCIEUhttps://www.ScientificEuropean.co.uk
Scientific European® | SCIEU.com | התקדמות משמעותית במדע. השפעה על המין האנושי. מוחות מעוררי השראה.

הירשם לניוזלטר שלנו

להתעדכן בכל החדשות האחרונות, ההצעות וההודעות המיוחדות.

הכי פופולרי כתבות

השפעות שונות (חיוביות ושליליות) של ניקוטין על המוח

לניקוטין יש מגוון עצום של השפעות נוירופיזיולוגיות, לא...

ניסויי תרופות נגד COVID-19 מתחילים בבריטניה ובארה"ב

ניסויים קליניים להערכת יעילות התרופה נגד מלריה, הידרוקסיכלורוקין...
- פרסום -
94,466אוהדיםכמו
47,680עוקביםעקבו
1,772עוקביםעקבו
30מנויהירשם